Cargando…

Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial

PURPOSE: To test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. METHODS AND MATERIALS: A total of 164 pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jin, Gu, Fei, Ji, Tianlong, Zhao, Jing, Li, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389381/ https://www.ncbi.nlm.nih.gov/pubmed/32727497 http://dx.doi.org/10.1186/s13014-020-01606-3

Ejemplares similares

Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer
por: Wang, Cong, et al.
Publicado: (2022)

The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer
por: Zhang, Bao-Zhong, et al.
Publicado: (2023)

Development of a nomogram for predicting grade 2 or higher acute hematologic toxicity of cervical cancer after the pelvic bone marrow sparing radiotherapy
por: Meng, Xiangdi, et al.
Publicado: (2022)

Effect of Pelvic Bone Marrow Sparing Intensity Modulated Radiation Therapy on Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemo-Radiotherapy
por: Huang, Wei, et al.
Publicado: (2021)

The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer
por: Yang, Xiaojing, et al.
Publicado: (2023)

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women
por: Wang, Weiping, et al.
Publicado: (2017)

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy: Comparison of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiation Therapy
por: Hui, Beina, et al.
Publicado: (2014)

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation
por: Kumar, T, et al.
Publicado: (2019)

Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
por: Qin, Xiaohang, et al.
Publicado: (2022)

Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy
por: Oike, Takahiro, et al.
Publicado: (2013)

The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy
por: Chen, Min, et al.
Publicado: (2023)

Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy
por: Wang, Shih-Chang, et al.
Publicado: (2018)

A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer
por: Chen, Hongbo, et al.
Publicado: (2023)

Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?
por: Hara, Jared H.L., et al.
Publicado: (2022)

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy
por: Vitzthum, Lucas K., et al.
Publicado: (2020)

Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
por: Shi, Feiya, et al.
Publicado: (2022)

Which Bone Marrow Sparing Strategy and Radiotherapy Technology Is Most Beneficial in Bone Marrow-Sparing Intensity Modulated Radiation Therapy for Patients With Cervical Cancer?
por: Yu, De-Yang, et al.
Publicado: (2020)

Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer
por: Bao, Zhirong, et al.
Publicado: (2019)

Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer
por: Wei, Li-Chun, et al.
Publicado: (2018)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy
por: Yamamoto, Takaya, et al.
Publicado: (2020)

Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
por: Kuncman, Łukasz, et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study
por: Baré, Mathilde, et al.
Publicado: (2022)

Symptom Clusters and Quality of Life in Cervical Cancer Patients Receiving Concurrent Chemoradiotherapy: The Mediating Role of Illness Perceptions
por: Zhang, Lan, et al.
Publicado: (2022)

Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
por: Wan, Juefeng, et al.
Publicado: (2015)

The volume of (99m)Tc sulfur colloid SPET‐defined active bone marrow can predict grade 3 or higher acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy
por: Wang, Shan‐Bing, et al.
Publicado: (2019)

Concurrent cisplatin-based chemoradiotherapy versus exclusive radiotherapy in high-risk cervical cancer: a meta-analysis
por: Meng, Xiang-Yu, et al.
Publicado: (2016)

Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging
por: Qin, Xiaohang, et al.
Publicado: (2022)

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
por: Kadkhodayan, Sima, et al.
Publicado: (2013)

Quality of Life in Cervical Cancer Survivors Treated with Concurrent Chemoradiotherapy
por: Stuopelytė, Raminta, et al.
Publicado: (2023)

Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
por: Wu, Yi-Feng, et al.
Publicado: (2019)

Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis
por: Fu, Zhan-Zhao, et al.
Publicado: (2017)

Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis
por: Yao, Ji-Jin, et al.
Publicado: (2017)

Changes in magnetic resonance T2-weighted imaging signal intensity correlate with concurrent chemoradiotherapy response in cervical cancer
por: Liu, Bing, et al.
Publicado: (2019)

Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma
por: Wei, Li-Chun, et al.
Publicado: (2013)

A comparison of concurrent chemoradiotherapy and radiotherapy in Chinese patients with locally advanced cervical carcinoma: a multi-center study
por: Li, Zhijie, et al.
Publicado: (2014)

Toxic epidermal necrolysis in a patient receiving concurrent phenytoin and whole brain and thoracic radiotherapy
por: Ahmed, Imtiaz, et al.
Publicado: (2014)

Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma
por: Martin, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sikqlndchlfjf8dcjgj9qn479t